Moderna/Merck-first out of the gate with a personal neoantigen cancer vaccine-who else is in the race and what strategy(ies) will win?
A commercial analysis positions Moderna/Merck as first out of the gate with a personalized neoantigen cancer vaccine and asks who else is in the race—and which strategies will win. Only the title was available, but the framing is the investor takeaway: with a first mover established, competitive differentiation now hinges on which strategies win rather than on proof-of-concept itself.